A Phase 3 interventional study of peginterferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 101 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-22.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 28th largest by enrollment, is one of 4 that started in 2008, is one of 19 in phase 3, and was the 40th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 235 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 23rd largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2008, is one of 9 in phase 3, and was the 23rd registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.
During a pre-study run-in phase patients with chronic hepatitis C genotype 2/3, who had started therapy with PEG-IFN alfa-2a plus ribavirin according to local standard of care and did not achieve a rapid viral response (RVR) (defined as Hepatitis C virus (HCV) RNA \<15 IU/mL at Week 4 of treatment measured with the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test) were eligible for the study and entered the screening phase between treatment Week 4 and 8 as soon as the result of the Week 4 HCV RNA test was available.
Eligible patients entered the study and continued with the dose regimens of PEG-IFN alfa-2a and ribavirin they were taking prior to enrolment into the trial up to Week 24 of treatment. Patients who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24, were randomized at treatment Week 24 to one of the two study groups. Upon randomization, participants either stopped treatment (equaling 24 weeks of treatment) or continued treatment for another 24 weeks (equaling 48 weeks of treatment). A treatment free follow-up period of 24 weeks (for participants in the 48-week treatment group) or 48 weeks (participants in the 24-week treatment group) completed the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
Drug: peginterferon alfa-2a · Drug: Ribavirin
After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
Drug: peginterferon alfa-2a · Drug: Ribavirin
Also known as: Pegasys®, PEG-IFN alfa-2a
Also known as: Copegus®
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment
Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) 24 weeks after scheduled treatment completion, defined as Week 44 or later for participants randomized to the 24-week treatment period or Week 68 or later for participants randomized to the 48-week treatment period. Participants without measurements at the end of the 24-week untreated follow-up period were considered non-responders in the analysis.
Time frame: 24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment
Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 24 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 24 weeks after actual end of treatment were used in the analysis. Participants without a 24-week post treatment measurement are considered non-responders.
Time frame: 24 weeks after actual end of treatment (range from Week 48 to Week 72).
Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation
Virological response 72 weeks after treatment initiation is defined as the percentage of participants with HCV RNA \<15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test at 48 weeks post completion of the 24 week treatment period and 24 weeks post completion of the 48 week treatment period. Participants without Week 72 measurements were considered non-responders in the analysis.
Time frame: Week 72
Percentage of Participants With Virological Response at End of Treatment
Virological response at the end of treatment was defined as the percentage of participants with HCV RNA \<15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test after the last dose of study medication.
Time frame: End of Treatment (Week 24 and Week 48 for each treatment group respectively).
Percentage of Participants With Virological Relapse
Virological relapse defined as the percentage of participants with a virological response at end of treatment but who did not have a sustained virological response 24 weeks after the end of treatment. Virological response at end of treatment is defined as a single last HCV RNA measurement \<15 IU/ml measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test at the day of last dose of study medication. Sustained virological response 24 weeks after the actual treatment end (SVR24) is defined as a single last HCV RNA measurement \<15 IU/ml at least 20 weeks after treatment end.
Time frame: End of treatment (Weeks 24 or 48) and 24 weeks after the end of treatment (weeks 48 and 72 in each treatment group respectively).
Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment
Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 12 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 12 weeks after actual end of treatment were used in the analysis. Participants without a 12-week post treatment measurement are considered non-responders.
Time frame: 12 weeks after actual end of treatment (range from Week 36 to Week 60)
Number of Participants With Adverse Events (AEs)
An AE was defined as a sign or symptom, including intercurrent illness, that occurred during the course of the clinical study after treatment had started. A related AE is an event assessed by the Investigator to be remotely, possibly, or probably related to study treatment according to criteria provided in the protocol. A severe AE was an event graded by the Investigator as "incapacitating with inability to work or perform normal daily activity". A serious AE (SAE) was defined as any experience that suggests a significant hazard, contraindication, side effect or precaution. This includes any experience which was fatal; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/ birth defect; was medically significant or required intervention to prevent one or other of the outcomes listed above.
Time frame: From Week 1 through Week 72.
Patients with Chronic Hepatitis C, Genotype 2 or 3 who had started therapy with PEG-IFN alfa-2a plus ribavirin according to local standard of care during a pre-study run-in phase and did not achieve a rapid viral response defined as HCV RNA \<15 IU/mL at Week 4 of treatment were eligible and entered the screening phase between treatment Weeks 4-8.
| Milestone | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Started | 95 | 93 |
| Completed | 95 | 66 |
| Not completed | 0 | 27 |
| Withdrew: Adverse event/intercurrent illness | 0 | 9 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Did not cooperate / refused treatment | 0 | 13 |
| Withdrew: Insufficient therapeutic response | 0 | 2 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Started | 95 | 93 |
| Completed | 66 | 78 |
| Not completed | 29 | 15 |
| Withdrew: Relapse post-treatment | 11 | 3 |
| Withdrew: Failure to return | 10 | 2 |
| Withdrew: Patient withdrew consent | 5 | 4 |
| Withdrew: Hcv-rna detectable at end of treatment | 2 | 1 |
| Withdrew: Did not cooperate | 0 | 3 |
| Withdrew: Reason not specified | 1 | 1 |
| Withdrew: Death | 0 | 1 |
Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) 24 weeks after scheduled treatment completion, defined as Week 44 or later for participants randomized to the 24-week treatment period or Week 68 or later for participants randomized to the 48-week treatment period. Participants without measurements at the end of the 24-week untreated follow-up period were considered non-responders in the analysis.
| percentage of participants | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment | 52 | 57 |
Virological response 72 weeks after treatment initiation is defined as the percentage of participants with HCV RNA \<15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test at 48 weeks post completion of the 24 week treatment period and 24 weeks post completion of the 48 week treatment period. Participants without Week 72 measurements were considered non-responders in the analysis.
| percentage of participants | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation | 44 | 57 |
Virological response at the end of treatment was defined as the percentage of participants with HCV RNA \<15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test after the last dose of study medication.
| percentage of participants | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Percentage of Participants With Virological Response at End of Treatment | 93 | 90 |
Virological relapse defined as the percentage of participants with a virological response at end of treatment but who did not have a sustained virological response 24 weeks after the end of treatment. Virological response at end of treatment is defined as a single last HCV RNA measurement \<15 IU/ml measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test at the day of last dose of study medication. Sustained virological response 24 weeks after the actual treatment end (SVR24) is defined as a single last HCV RNA measurement \<15 IU/ml at least 20 weeks after treatment end.
| percentage of participants | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Percentage of Participants With Virological Relapse | 41 | 29 |
Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 24 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 24 weeks after actual end of treatment were used in the analysis. Participants without a 24-week post treatment measurement are considered non-responders.
| percentage of participants | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment | 52 | 61 |
Sustained virological response (SVR) is defined as a single last HCV RNA measurement \<15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 12 weeks after actual end of study treatment. For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 12 weeks after actual end of treatment were used in the analysis. Participants without a 12-week post treatment measurement are considered non-responders.
| percentage of participants | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment | 52 | 61 |
An AE was defined as a sign or symptom, including intercurrent illness, that occurred during the course of the clinical study after treatment had started. A related AE is an event assessed by the Investigator to be remotely, possibly, or probably related to study treatment according to criteria provided in the protocol. A severe AE was an event graded by the Investigator as "incapacitating with inability to work or perform normal daily activity". A serious AE (SAE) was defined as any experience that suggests a significant hazard, contraindication, side effect or precaution. This includes any experience which was fatal; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/ birth defect; was medically significant or required intervention to prevent one or other of the outcomes listed above.
| participants | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Any AE | 81 | 88 |
| Severe AE | 13 | 24 |
| AE related to PEG-IFN alfa-2a | 78 | 86 |
| AE related to ribavirin | 72 | 83 |
| Serious AE | 4 | 11 |
| SAE related to PEG-IFN alfa-2a | 0 | 7 |
| SAE related to ribavirin | 0 | 4 |
| Deaths | 0 | 1 |
Collected over 72 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | — | 4/95 (4.2%) | 81/95 (85.3%) |
| PEG-IFN Alfa-2a + Ribavirin for 48 Weeks | — | 11/93 (11.8%) | 87/93 (93.5%) |
| Event | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| Psychotic disorderPsychiatric disorders | 0/95 | 1/93 |
| DepressionPsychiatric disorders | 0/95 | 1/93 |
| AnaemiaBlood and lymphatic system disorders | 1/95 | 1/93 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/95 | 1/93 |
| Rectal haemorrhageGastrointestinal disorders | 0/95 | 1/93 |
| VomitingGastrointestinal disorders | 0/95 | 1/93 |
| CellulitisInfections and infestations | 0/95 | 1/93 |
| SepsisInfections and infestations | 0/95 | 1/93 |
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/95 | 1/93 |
| Cerebrovascular accidentNervous system disorders | 0/95 | 1/93 |
| Event | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks |
|---|---|---|
| FatigueGeneral disorders | 33/95 | 47/93 |
| HeadacheNervous system disorders | 17/95 | 30/93 |
| NauseaGastrointestinal disorders | 13/95 | 24/93 |
| InsomniaPsychiatric disorders | 21/95 | 21/93 |
| PruritusSkin and subcutaneous tissue disorders | 17/95 | 20/93 |
| MyalgiaMusculoskeletal and connective tissue disorders | 8/95 | 18/93 |
| AstheniaGeneral disorders | 18/95 | 14/93 |
| AlopeciaSkin and subcutaneous tissue disorders | 15/95 | 17/93 |
| Decreased appetiteMetabolism and nutrition disorders | 8/95 | 15/93 |
| Dry skinSkin and subcutaneous tissue disorders | 13/95 | 14/93 |
| Age Continuous(years) | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks | Total |
|---|---|---|---|
| Mean | 48.8 ± 9.83 | 48.6 ± 10.12 | 48.7 ± 9.95 |
| Age, Customized(participants) | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks | Total |
|---|---|---|---|
| ≤ 50 years | 47 | 53 | 100 |
| > 50 years | 48 | 40 | 88 |
| Sex: Female, Male(Participants) | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks | Total |
|---|---|---|---|
| Female | 40 | 39 | 79 |
| Male | 55 | 54 | 109 |
| Race/Ethnicity, Customized(participants) | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks | Total |
|---|---|---|---|
| Caucasian or white | 82 | 81 | 163 |
| Black | 8 | 6 | 14 |
| Asian or oriental | 1 | 2 | 3 |
| Other | 4 | 4 | 8 |
| Hepatitis C virus (HCV) genotype(participants) | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks | Total |
|---|---|---|---|
| HCV Genotype 2 | 19 | 19 | 38 |
| HCV Genotype 3 | 76 | 74 | 150 |
| Pre-treatment HCV ribonucleic acid (RNA)(log10 IU/mL) | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks | Total |
|---|---|---|---|
| Mean | 6.11 ± 0.624 | 6.17 ± 0.773 | 6.14 ± 0.700 |
| Region(participants) | PEG-IFN Alfa-2a + Ribavirin for 24 Weeks | PEG-IFN Alfa-2a + Ribavirin for 48 Weeks | Total |
|---|---|---|---|
| Non-U.S. | 85 | 82 | 167 |
| U.S. | 10 | 11 | 21 |
Showing the first 100 of 101 sites across 10 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2008, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin